Legal Action Against Rocket Pharmaceuticals: Investors Urged to Act
On July 17, 2025, The Gross Law Firm announced significant legal developments surrounding Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This announcement is particularly vital for shareholders who acquired RCKT stock between February 27, 2025, and May 26, 2025. Allegations have surfaced indicating that Rocket Pharmaceuticals failed to disclose crucial information about the safety and clinical trial protocols of its therapy, RP-A501. The firm is urging impacted investors to reach out for potential lead plaintiff roles, although such roles are not a prerequisite for participating in any recovery made through the class action.
The allegations state that Rocket Pharmaceuticals provided overly positive statements to investors while simultaneously hiding critical adverse information. Specifically, it is revealed that the company was aware of serious adverse events (SAEs), including patient fatalities involved in the clinical study, but failed to inform shareholders about these risks. In fact, Rocket amended its trial protocol to include a new immunomodulatory agent without alerting investors about this change at the time it occurred. This lack of transparency resulted in shareholders buying Rocket's securities at artificially inflated prices, which has now raised legal concerns.
On May 27, 2025, Rocket Pharmaceuticals disclosed that the FDA imposed a clinical hold on the RP-A501 Phase 2 pivotal study, triggered by at least one participant suffering a SAE that resulted in death. Further complicating matters, it was reported that the decision to amend the trial's protocol occurred 'several months' prior to the dosing in May, and this critical information was never communicated to investors until after the SAE was reported. This led to a significant drop in Rocket's stock price—from $6.27 per share on May 23, 2025, to $2.33 by May 27, marking a staggering decrease of approximately 37% in less than 24 hours.
The Gross Law Firm encourages all shareholders who acquired shares of Rocket during the specified class period to register for action against the company. The deadline to file for lead plaintiff status is August 11, 2025. In line with this, the law firm will monitor the status of the case and provide updates to those who register.
The Gross Law Firm is recognized nationally for advocating on behalf of investors who have incurred losses due to deceitful business practices. Their mission aims to safeguard investors' rights against companies that engage in misleading practices. According to the firm, accountability and adherence to responsible business practices are paramount, particularly when it comes to protecting investors from losses resulting from false or misleading statements.
For those who are stakeholders in Rocket Pharmaceuticals, immediate action is important. The Gross Law Firm emphasizes that participating in the class action comes with no related costs or obligations. Potential participants can visit the firm's website to submit their information regarding the case.
With the August deadline fast approaching, Rocket Pharmaceuticals shareholders are urged to take necessary steps to safeguard their investments. As the case develops, it may pave the way for significant implications for the company and possibly generate recuperative actions for investors impacted by the recent downturn in share prices.
The allegations state that Rocket Pharmaceuticals provided overly positive statements to investors while simultaneously hiding critical adverse information. Specifically, it is revealed that the company was aware of serious adverse events (SAEs), including patient fatalities involved in the clinical study, but failed to inform shareholders about these risks. In fact, Rocket amended its trial protocol to include a new immunomodulatory agent without alerting investors about this change at the time it occurred. This lack of transparency resulted in shareholders buying Rocket's securities at artificially inflated prices, which has now raised legal concerns.
On May 27, 2025, Rocket Pharmaceuticals disclosed that the FDA imposed a clinical hold on the RP-A501 Phase 2 pivotal study, triggered by at least one participant suffering a SAE that resulted in death. Further complicating matters, it was reported that the decision to amend the trial's protocol occurred 'several months' prior to the dosing in May, and this critical information was never communicated to investors until after the SAE was reported. This led to a significant drop in Rocket's stock price—from $6.27 per share on May 23, 2025, to $2.33 by May 27, marking a staggering decrease of approximately 37% in less than 24 hours.
The Gross Law Firm encourages all shareholders who acquired shares of Rocket during the specified class period to register for action against the company. The deadline to file for lead plaintiff status is August 11, 2025. In line with this, the law firm will monitor the status of the case and provide updates to those who register.
The Gross Law Firm is recognized nationally for advocating on behalf of investors who have incurred losses due to deceitful business practices. Their mission aims to safeguard investors' rights against companies that engage in misleading practices. According to the firm, accountability and adherence to responsible business practices are paramount, particularly when it comes to protecting investors from losses resulting from false or misleading statements.
For those who are stakeholders in Rocket Pharmaceuticals, immediate action is important. The Gross Law Firm emphasizes that participating in the class action comes with no related costs or obligations. Potential participants can visit the firm's website to submit their information regarding the case.
With the August deadline fast approaching, Rocket Pharmaceuticals shareholders are urged to take necessary steps to safeguard their investments. As the case develops, it may pave the way for significant implications for the company and possibly generate recuperative actions for investors impacted by the recent downturn in share prices.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.